Literature DB >> 14630263

Intrafractional stability of the prostate using a stereotactic radiotherapy technique.

Berit L Madsen1, R Alex Hsi, Huong T Pham, Joseph Presser, Laura Esagui, John Corman, Lee Myers, Douglas Jones.   

Abstract

PURPOSE: To evaluate the stability of the prostate during stereotactic radiation therapy.
MATERIALS AND METHODS: Forty-seven patients underwent placement of three fiducial markers into the prostate as part of a pilot study of hypofractionated stereotactic radiotherapy. Portal images before and subsequent to 227 radiotherapy fractions were analyzed for prostate movement. Six patients also underwent localizing radiographs at 6-min intervals for 24 min. Relative motion of the bony landmarks and prostate markers was calculated.
RESULTS: Analysis of portal images revealed the undirected average prostate movement of 2.0 mm (superior/inferior), 1.9 mm (anterior/posterior), and 1.4 mm (right/left) with maximum standard deviation (SD) of 2.0. Analysis of radiographs at 6-min intervals showed the greatest undirected average prostate motion between 0-6 min; 1.5 mm (superior/inferior), 1.4 mm (anterior/posterior), and 0.4 mm (right/left). Beyond 6 min, movements decreased to 0.4, 0.9, and 0.8 mm, respectively. Bony landmark motion was 0.9 mm (superior/inferior), 0.9 mm (anterior/posterior), and 0.4 mm (right/left) between 0-6 min. Beyond 6 min, motion decreased to less than 0.5 mm in any direction.
CONCLUSIONS: Stereotactic prostate radiotherapy, utilizing fiducial marker localization, resulted in average intrafractional prostate movement of 2.0 mm or less. Most patient and organ movement occurs early and a settling-in period is advisable before treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14630263     DOI: 10.1016/s0360-3016(03)00746-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Prostate intrafraction motion evaluation using kV fluoroscopy during treatment delivery: a feasibility and accuracy study.

Authors:  Justus Adamson; Qiuwen Wu
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

2.  Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Authors:  Michael Wahl; Martina Descovich; Erin Shugard; Dilini Pinnaduwage; Atchar Sudhyadhom; Albert Chang; Mack Roach; Alexander Gottschalk; Josephine Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-08

3.  Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments.

Authors:  Marta Scorsetti; Filippo Alongi; Simona Castiglioni; Alessandro Clivio; Antonella Fogliata; Francesca Lobefalo; Pietro Mancosu; Pierina Navarria; Valentina Palumbo; Chiara Pellegrini; Sara Pentimalli; Giacomo Reggiori; Anna M Ascolese; Antonella Roggio; Stefano Arcangeli; Angelo Tozzi; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2011-09-12       Impact factor: 3.481

4.  Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.

Authors:  Mark E Hwang; Mark Mayeda; Hiram Shaish; Carl D Elliston; Catherine S Spina; Sven Wenske; Israel Deutsch
Journal:  Br J Radiol       Date:  2021-02-15       Impact factor: 3.039

5.  Dosimetric effects of prone and supine positions on post-implant assessments for prostate brachytherapy.

Authors:  Toshio Ohashi; Tetsuo Momma; Shoji Yamashita; Kunimitsu Kanai; Yusuke Watanabe; Takashi Hanada; Naoyuki Shigematsu
Journal:  J Contemp Brachytherapy       Date:  2013-09-20

6.  Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT.

Authors:  Judit Boda-Heggemann; Frederick Marc Köhler; Hansjörg Wertz; Michael Ehmann; Brigitte Hermann; Nadja Riesenacker; Beate Küpper; Frank Lohr; Frederik Wenz
Journal:  Radiat Oncol       Date:  2008-11-05       Impact factor: 3.481

7.  SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Authors:  Monika Rucinska; Anna Kieszkowska-Grudny; Sergiusz Nawrocki
Journal:  Strahlenther Onkol       Date:  2016-05-25       Impact factor: 3.621

8.  Impact of rectal balloon-filling materials on the dosimetry of prostate and organs at risk in photon beam therapy.

Authors:  Shiv P Srivastava; Indra J Das; Arvind Kumar; Peter A S Johnstone; Chee-Wai Cheng
Journal:  J Appl Clin Med Phys       Date:  2013-01-07       Impact factor: 2.102

9.  Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.

Authors:  J Schaule; M Chamberlain; L Wilke; M Baumgartl; J Krayenbühl; M Zamburlini; M Mayinger; N Andratschke; S Tanadini-Lang; M Guckenberger
Journal:  Radiat Oncol       Date:  2021-09-26       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.